Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Canada's Population Health Model (POHEM): a tool for performing economic evaluations of cancer control interventions.

Will BP, Berthelot JM, Nobrega KM, Flanagan W, Evans WK.

Eur J Cancer. 2001 Sep;37(14):1797-804.

PMID:
11549434
2.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

3.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

4.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

5.

Economic and cost-effectiveness issues in breast cancer treatment.

Hillner BE.

Semin Oncol. 1996 Feb;23(1 Suppl 2):98-104. Review.

PMID:
8614853
6.

Economic analyses and lung cancer.

Vergnen├Ęgre A, Molinier L, Choua├»d C.

Monaldi Arch Chest Dis. 2001 Aug;56(4):336-43. Review.

PMID:
11770217
7.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
8.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

9.

A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.

Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, Sculpher M, Eastwood A.

Health Technol Assess. 2008 Jan;12(1):iii-iv, xi-xii, 1-147. Review.

10.

Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer.

Carlson JJ, Veenstra DL, Ramsey SD.

Drugs. 2008;68(8):1105-13. Review.

PMID:
18484801
11.

Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).

Grossi F, Tiseo M.

Crit Rev Oncol Hematol. 2006 Jun;58(3):221-30. Epub 2006 May 11. Review.

PMID:
16697211
12.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

13.

Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis.

Mohan HK, Miles KA.

J Nucl Med. 2009 Mar;50(3):376-81. doi: 10.2967/jnumed.108.055988. Epub 2009 Feb 17. Review.

14.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

15.
16.

Economic issues in lung cancer: a review.

Goodwin PJ, Shepherd FA.

J Clin Oncol. 1998 Dec;16(12):3900-12. Review.

PMID:
9850036
17.

Management of advanced lung cancer in resource-constrained settings: a perspective from India.

Singh N, Aggarwal AN, Behera D.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1479-95. doi: 10.1586/era.12.119. Review.

PMID:
23249112
18.

Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010.

Sanz-Granda A, Hidalgo A, del Llano JE, Rovira J.

Clin Transl Oncol. 2013 Jan;15(1):9-19. doi: 10.1007/s12094-012-0934-8. Epub 2012 Nov 21. Review.

PMID:
23180344
19.

Economic considerations in the care of lung cancer patients.

Desch CE, Hillner BE, Smith TJ.

Curr Opin Oncol. 1996 Mar;8(2):126-32. Review.

PMID:
8727305
20.

The cost of managing lung cancer in Canada.

Evans WK, Will BP, Berthelot JM, Wolfson MC.

Oncology (Williston Park). 1995 Nov;9(11 Suppl):147-53. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk